Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...

Bristol-Myers Squibb shares rose in premarket trade on Friday after the Food and Drug Administration approved a schizophrenia ...

This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...

Bristol Myers Squibb's Cobenfy has been approved by the FDA as the first new treatment for schizophrenia in decades. The ...

Analyst Chris Shibutani from Goldman Sachs reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report) and keeping the price ...

In a report released yesterday, Carter Gould from Barclays maintained a Sell rating on Bristol-Myers Squibb (BMY – Research Report), with ...

As of now, Bristol Myers Squibb has registered a Year-to-Date (YTD) stock performance of +1.48%. This figure starkly contrasts with the S&P 500’s impressive YTD performance of +20.45%. While BMY’s ...

Bristol-Myers Squibb won Food and Drug Administration approval late Thursday for its novel schizophrenia drug, Cobenfy. BMY ...

Shares jumped 6% in premarket trading after the Food and Drug Administration approved a treatment for [schizophrenia patients]( ...

Bristol Myers Squibb (BMY) ended the recent trading session at $49.95, demonstrating a +0.46% swing from the preceding day's closing price. This move lagged the S&P 500's daily gain of 1.01%.

While not a mind-blowing move, it is good to see that the Bristol-Myers Squibb Company (NYSE:BMY) share price has gained 22% in the last three months. But that doesn't help the fact that the three ...